ARID1A and neuroblastoma: However, Sausen and colleagues recently found that ARID1A or ARID1B mutations associate with worse OS in patients with neuroblastoma, and a previous breast cancer study noted that decreased ARID1A expression can confer worse prognosis (Mamo et al., 2012; Sausen et al., 2013).